

## FORM 51-102F3 - MATERIAL CHANGE REPORT

1. **NAME AND ADDRESS OF COMPANY**

Telo Genomics Corp.  
MaRS Centre, South Tower  
101 College Street, Suite 200  
Toronto, Ontario M5G 1L7

2. **DATE OF MATERIAL CHANGE**

December 8, 2023

3. **NEWS RELEASE**

News release dated December 8, 2023 was disseminated via Stockwatch

4. **SUMMARY OF MATERIAL CHANGE**

Telo Genomics Corp. announces Management Change

5. **FULL DESCRIPTION OF MATERIAL CHANGE**

Telo Genomics Corp. (TSX-V: TELO) (OTCQB: TDSGF) (the “**Company**”) announced that Kris Weinberg has stepped down as the Chief Executive Officer (“**CEO**”) of the Company. The Company thanks Mr. Weinberg for his valuable contributions and wishes him the best in his future endeavors.

In connection with Mr. Weinberg’s resignation, Telo Genomics is pleased to announce that it has appointed Dr. Sabine Mai as the Company’s interim CEO. Dr. Mai founded the Company, created Telo Genomics’ proprietary technology, and has acted as a director of the Company since 2016. Dr. Mai is the Canada Research Chair (Tier 1) in Genomic Instability and Nuclear Architecture of Cancer, as well as a Professor of Physiology and Pathophysiology, Biochemistry and Medical Genetics, Human Anatomy and Cell Science at the University of Manitoba. Dr. Mai is also a director of The Genomic Centre for Cancer Research and Diagnosis (GCCRD) at the University of Manitoba.

In connection with Dr. Mai’s appointment as interim CEO, the Company has granted her 200,000 stock options (the “**Options**”) to purchase up to 200,000 common shares of the Company, pursuant to the Company’s 2022 stock option plan. The Options are exercisable at \$0.20 for a period of five years from the date of grant.

Dr. Mai remains a director and the Chair of the Clinical and Scientific Advisory Board of Telo Genomics.

6. **RELIANCE ON SUBSECTION 7.1(2) OF NATIONAL INSTRUMENT 51-102**

Not applicable.

7. **OMITTED INFORMATION**

Not applicable.

8. **EXECUTIVE OFFICER**

Christopher Ross  
416-673-8487  
info@telodx.com

9. **DATE OF REPORT**

December 8, 2023